التفاصيل البيبلوغرافية
| العنوان: |
HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE |
| Document Number: |
20110014220 |
| تاريخ النشر: |
January 20, 2011 |
| Appl. No: |
12/505998 |
| Application Filed: |
July 20, 2009 |
| مستخلص: |
The present invention relates to a vaccine composition against the infection of human respiratory syncytial virus (RSV) comprising a replication-defective recombinant adenovirus carrying a nucleotide sequence encoding the F protein of RSV or fragment thereof. A method of preventing RSV infection-related diseases using the vaccine composition of the present invention is also provided. |
| Inventors: |
Chow, Yen-Hung (Zhunan Town, TW); Shao, Hsiao-Yun (Zhunan Town, TW); Sia, Charles (Zhunan Town, TW); Chong, Pele (Zhunan Town, TW) |
| Assignees: |
National Health Research Institutes (Zhunan Town, TW) |
| Claim: |
1. A vaccine composition for the prophylaxis of RSV infection or respiratory syncytial virus (RSV) infection-related diseases comprising an effective amount of a replication-defective recombinant adenoviral construct carrying a nucleotide sequence encoding F protein of RSV or fragments thereof. |
| Claim: |
2. The vaccine composition of claim 1, wherein the RSV is human RSV. |
| Claim: |
3. The vaccine composition of claim 2, wherein the nucleotide sequence encodes the full length of F protein of human RSV. |
| Claim: |
4. The vaccine composition of claim 1, wherein the nucleotide sequence encodes F protein of RSV having the amino acid sequence of SEQ ID NO: 2. |
| Claim: |
5. The vaccine composition of claim 1, wherein the nucleotide sequence encoding F protein of RSV has the nucleotide sequence of SEQ ID NO: 1. |
| Claim: |
6. The vaccine composition of claim 1, wherein the nucleotide sequence encodes a fragment of F protein of RSV is transmembrane coding region-truncated F protein. |
| Claim: |
7. The vaccine composition of claim 5, wherein the nucleotide sequence encodes a fragment of F protein of RSV having the amino acid sequence of SEQ ID NO: 4. |
| Claim: |
8. The vaccine composition of claim 5, wherein nucleotide sequence encoding a fragment of F protein of RSV has the nucleotide sequence of SEQ ID NO: 3. |
| Claim: |
9. The vaccine composition of claim 1, wherein the replication-defective adenovirus is a serotype 5 adenovirus (Ad5). |
| Claim: |
10. The vaccine composition of claim 9, wherein the recombinant adenoviral construct is derived from a replication-defective adenovirus with deletions in its E1 and E3 genes. |
| Claim: |
11. The vaccine composition of claim 1, wherein the RSV infection-related disease is selected from the group consisting of otitis media, bronchilitis, eosinophilia and pneumonia. |
| Claim: |
12. The vaccine composition of claim 1, which is administered transmucosally. |
| Claim: |
13. The vaccine composition of claim 11, which is administered intranasally. |
| Claim: |
14. A method of preventing RSV infection or RSV infection-related diseases comprising administering to a subject in need thereof a vaccine composition comprising an effective amount of a replication-defective recombinant adenoviral construct carrying a nucleotide sequence encoding a polypeptide of F protein of RSV or fragments thereof. |
| Claim: |
15. The method of claim 14, wherein the RSV is human RSV. |
| Claim: |
16. The method of claim 15, wherein the nucleotide sequence encodes the full length of F protein of human RSV. |
| Claim: |
17. The method of claim 14, wherein the nucleotide sequence encodes F protein of RSV having the amino acid sequence of SEQ ID NO: 2. |
| Claim: |
18. The method of claim 14, wherein the nucleotide sequence encoding F protein of RSV has the nucleotide sequence of SEQ ID NO: 1. |
| Claim: |
19. The method of claim 14, wherein the nucleotide sequence encodes a fragment of F protein of RSV is transmembrane coding region-truncated F protein. |
| Claim: |
20. The method of claim 19, wherein the nucleotide sequence encodes a fragment of F protein of RSV having the amino acid sequence of SEQ ID NO: 4. |
| Claim: |
21. The method of claim 19, wherein nucleotide sequence encoding a fragment of F protein of RSV has the nucleotide sequence of SEQ ID NO: 3. |
| Claim: |
22. The method of claim 14, wherein the replication-defective adenovirus is a serotype 5 adenovirus (Ad5). |
| Claim: |
23. The method of claim 22, wherein the recombinant adenoviral construct is derived from a replication-defective adenovirus with deletions in its E1 and E3 genes. |
| Claim: |
24. The method of claim 14, wherein the RSV infection-related disease is selected from the group consisting of otitis media, bronchilitis, eosinophilia and pneumonia. |
| Claim: |
25. The method of claim 14, wherein the vaccine composition is administered transmucosally. |
| Claim: |
26. The method of claim 11, wherein the vaccine composition is administered intranasally. |
| Current U.S. Class: |
4241/861 |
| Current International Class: |
61; 61 |
| رقم الانضمام: |
edspap.20110014220 |
| قاعدة البيانات: |
USPTO Patent Applications |